Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neurofibromatoses × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 33 Leukemia 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Leukemia, Myeloid, Chronic-Phase 12 Gastrointestinal Stromal Tumors 12 Philadelphia Chromosome 5 Leukemia, Myeloid 5 Brain Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Blast Crisis 4 Recurrence 3 Prostatic Neoplasms 3 Melanoma 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Hematologic Diseases 3 Glioblastoma 3 Bone Marrow Diseases 3 Stomach Neoplasms 2 Sarcoma 2 Ovarian Neoplasms 2 Neoplasms by Histologic Type 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Meningioma 2 Leukemia, Myeloid, Accelerated Phase 2 Gliosarcoma 2 Glioma 2 Digestive System Neoplasms 2 Carcinoma, Renal Cell 2

Interventions

tipifarnib 1 nilotinib 1 mirdametinib 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Lidocaine 1 Imatinib Mesylate 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡